Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Galapagos  /  Galapagos juni 2019

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Galapagos AEX:GLPG.NL, BE0003818359

  • 26,840 25 apr 2024 13:54
  • -0,280 (-1,03%) Dagrange 26,740 - 26,980
  • 30.573 Gem. (3M) 80,8K

Galapagos juni 2019

2.736 Posts
Pagina: «« 1 ... 74 75 76 77 78 ... 137 »» | Laatste | Omlaag ↓
  1. BLOO7 14 juni 2019 15:07
    quote:

    durobinet schreef op 14 juni 2019 15:03:

    [...]

    Dat waren calls en ik las net dat de koers begon te stijgen vanaf dat moment tot nu 109. Niet erg verkeerd lijkt me. Graag bij de feiten blijven en zakelijk zonder persoonlijk te worden.
    Neen, ik doe geen moeite om dat aanmodderen te gaan herlezen...
  2. BLOO7 14 juni 2019 15:22
    Morgen:

    Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis Naïve to Methotrexate Therapy: FINCH3 Primary Outcome Results (oral #LB0003 8:00am CET, 15 June, Hall 7B

    Volgens mij vielen bij dit onderzoek fase 3 bij Abbvie, een hoop doden.

    Tijd voor een promo-PB van Gilead zou ik zo zeggen.
  4. HansGarrincha 14 juni 2019 15:37
    www.evaluate.com/vantage/articles/eve...

    Galapagos hoping to branch out with filgotinib

    Much of the attention surrounding Galapagos’s filgotinib has focused on the group’s clinical success in rheumatoid arthritis. But later this year, the Belgian group will unveil proof of concept data for the Jak inhibitor in the niche disorders cutaneous lupus erythematosus (CLE) and Sjögren's syndrome.

    The indications offer two very distinct opportunities for Galapagos to extend the figotinib franchise. First to read out could be a 47-patient trial in CLE, a skin condition often associated with the more common systemic lupus erythematosus (SLE). Data in Sjögren's, a chronic, inflammatory autoimmune disease characterised by severe dryness of skin, eyes and mouth, ought to appear a few months later.

    What will count in filgotinib’s favour in CLE is the current dearth of treatments. But Galapagos is not alone in looking at the opportunity. Biogen’s BIIB059 is currently being tested in 320 patients in a phase II trial, due to read out by the end of the year, and results from this drug's small phase I study have been encouraging. The Biogen trial size is a stark contrast to Galapagos’s efforts: the phase II trial's design means that only 15-20 people with CLE are likely to be dosed with the drug.

    If Galapagos does prevail analysts at Bernstein estimate the potential market opportunity at $500m. So far, though, lupus has proved notoriously tricky to treat.

    In Sjögren's syndrome filgotinib’s prospects arguably look slightly brighter. Again, no approved treatment for the disorder exists, and the unmet need is greater with estimates of up to four million Sjögren's patients in the US. Bernstein analysts have put the total market opportunity here at $1bn.

    In a 48-week phase II trial filgotinib is being tested in 152 adults with Sjögren's, with a primary endpoint of patient-reported improvements in their condition. However, this endpoint is not based on any measure recognised by the industry, which could potentially make approval trickier.

    Also, while the CLE pipeline is relatively thin in Sjögren's there are substantially more projects in R&D – many ahead of Galapagos's candidate. Bristol-Myers Squibb has an ongoing phase III trial with its rheumatoid arthritis product Orencia, but results so far have been mixed. Novartis is testing two products in the disorder, the anti-CD40 mAb iscalimab and the BAFF mAb ianalumab. Both are currently in phase II and could be filed by 2023.

    Despite these not inconsiderable challenges to filgotinib’s success in both CLE and Sjögren's, Galapagos is sensibly trying to differentiate its late-to-the-party drug from the other Jak inhibitors on the market. And while history has shown success in lupus and its related conditions is almost impossible, if filgotinib does triumph it would provide very welcome revenue for both Galapagos and partner Gilead.
  7. [verwijderd] 14 juni 2019 16:07
    even een vraagje: hoe groot zijn de voorbeurs/nabeurs volumes eigenlijk, want ik krijg n beetje het idee dat de koers soms na/voor beurs met een (procentueel gezien) heel gering aantal stukken soms een flink stuk lager word gezet waarnaar er vervolgens op de handelsdag zeer veel kopers nodig zijn om deze daling weer goed te maken
  8. [verwijderd] 14 juni 2019 16:21
    quote:

    soga palag schreef op 14 juni 2019 16:07:

    even een vraagje: hoe groot zijn de voorbeurs/nabeurs volumes eigenlijk, want ik krijg n beetje het idee dat de koers soms na/voor beurs met een (procentueel gezien) heel gering aantal stukken soms een flink stuk lager word gezet waarnaar er vervolgens op de handelsdag zeer veel kopers nodig zijn om deze daling weer goed te maken
    volgens mij verwaasloosbaar.
  13. [verwijderd] 14 juni 2019 17:33
    quote:

    Opperste schreef op 14 juni 2019 08:18:

    Koers blijft gehele (komende) week om en bij 110.

    Die drukte om dat nietszeggende PB-tje Pfffff.

    MM vanwaar de verbazing??
    Beetje belegger ziet dit aankomen.
    Komende week blijft de koers ook om en bij 110.
    Dus vanwaar je ergernis? Je weet het nu toch??!
  17. HansGarrincha 14 juni 2019 17:47
    www.medscape.com/viewarticle/914372?s...
    MADRID — For patients with rheumatoid arthritis whose response to methotrexate is inadequate, filgotinib, an oral Janus kinase 1 (JAK1) inhibitor, leads to significant improvement, early data from the FINCH 1 trial (NCT02889796) suggest.

    Filgotinib could become the third drug in its class to be approved for rheumatoid arthritis, and its effectiveness and ease of use makes it a potential monotherapy, said investigator Bernard Combe, MD, PhD, from Montpellier University in France.

    "It's a very important finding." JAK inhibitors will probably be the leading treatment in rheumatoid arthritis in the near future, at the same level as TNF drugs, he said here at the European League Against Rheumatism (EULAR) 2019 Congress.

    The data are in line with "what I've seen with previous JAK inhibitors," Combe told Medscape Medical News. "What is maybe different here is filgotinib is specifically a JAK1 inhibitor, so the mechanism of action is slightly different than the two others."

    Those two JAK inhibitors — baricitinib (Olumiant, Eli Lilly) and tofacitinib (Xeljanz, Pfizer) — currently approved by the US Food and Drug Administration and the European Medicines Agency to treat rheumatoid arthritis both target the JAK pathway to ease inflammation.

    Combe presented interim primary outcome results from the 52-week phase 3, double-blind, placebo-controlled international FINCH 1 trial.

    FINCH 1 Trial
    The study participants, 81.8% of whom were female, had moderate to severe rheumatoid arthritis for an average of 7 to 8 years, had an inadequate response to at least 12 weeks of methotrexate, and had been on a stable dose of methotrexate for at least 4 weeks immediately before randomization to one of four treatment groups.

  18. HansGarrincha 14 juni 2019 17:47
    At week 24, ACR20, ACR50, and ACR70 response rates in the adalimumab group were similar to those in the filgotinib groups.

    When the percentage of patients with low disease activity (DAS28-CRP = 3.2) was assessed, filgotinib 200 mg was considered noninferior to adalimumab.

    There were no significant safety differences between the study groups, and rates of serious infections, venous thrombosis, and other adverse events were low. Serious infections were slightly higher in the filgotinib groups than in the placebo group, and were higher in all those groups than in the adalimumab group.

    The relatively high response rates in the placebo group were not a surprise, said Combe, who noted that the trial is ongoing, "so we're looking for an explanation." Participants from Eastern Europe had a much higher placebo responses than those in North America and Western Europe, he added.

    Filgotinib could be an alternative JAK inhibitor for RA, if it's approved.
    Because participants had taken methotrexate before baseline, "there could still be a methotrexate effect during the trial," despite the seeming inadequate response before data were collected, he pointed out.

    This trial is "huge" compared with others testing JAK inhibitors in rheumatoid arthritis, said Thomas Dörner, MD, from Charité Universitätsmedizin Berlin, who is chair of the EULAR scientific program committee.

    He said he agrees that the apparent effects of filgotinib in patients with rheumatoid arthritis are similar to the effects of other JAK inhibitors, and that it might be useful as a monotherapy.

    "The safety profile also looks comparable to what we've seen for other compounds, so I think this represents what one would expect in this class of molecules in a phase 3 trial," Dörner told Medscape Medical News.

    "For me, this is a successful trial," he added. "It's convincing, and filgotinib could be an alternative JAK inhibitor for RA, if it's approved."

    Additional data are needed, including safety data, said Combe, but filgotinib is "clearly promising" and "we can assume that the likelihood of it being on the market within 2 years is very good."

    Combe is a consultant for AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Eli Lilly, MSD, Novartis, Pfizer, Roche-Chugai, Sanofi, and UCB. Dörner receives grant/research support or is a consultant for Eli Lilly, Janssen, Roche, and UCB Pharma, and is a member of the speakers' bureau for Eli Lilly and Janssen.

    European League Against Rheumatism (EULAR) 2019 Congress: Abstract LB0001. Presented June 12, 2019.
  20. [verwijderd] 14 juni 2019 17:50
    quote:

    Sentiment schreef op 14 juni 2019 17:42:

    Ik geloof niet in complotten, maar de koers zit wel door handelaren in een wurggreep.
    Wat ook de bedoeling is, dat gaan ze niet volhouden, op een dag zijn hun aandelen op.
    Wie weet wat voor moois er dit weekend komt.
    Huh?

    invst.ly/b0ljl

    vanaf 3/6 ruim 8% gestegen......
    ergo: geen wurggreep, maar:

    1. Er zijn mondiaal wat spanningen
    2. VS-China
    3. Wat minnen op macro economisch gebied
    4. Koers GLPG loopt tegen ATH aan.

    Kortom ff wat gas terug.

2.736 Posts
Pagina: «« 1 ... 74 75 76 77 78 ... 137 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Weinig houvast voor beleggers in Galapagos

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Galapagos Nieuws

  1. 12 apr KBC Securities verlaagt koersdoel Galapagos naar 50 euro
  2. 05 apr Galapagos toont innovatieve aanpak in hematologische kankerzorg
  3. 23 feb AEX op de waakvlam het weekend in, koersdreun Besi, Alfen en Galapagos 2
  4. 23 feb Beursblik: gebrek aan opwaarts potentieel voor Galapagos op korte termijn
  5. 23 feb Gaat AEX op recordjacht of gaat de beursweek uit als een nachtkaars?
  6. 23 feb Update : Galapagos voldoet aan verwachtingen
  7. 19 feb Beursblik: cashburn belangrijk voor Galapagos
  8. 15 feb Galapagos presenteert nieuwe onderzoeksdata op EBMT-EHA bijeenkomst
  9. 01 feb Galapagos rondt Jyseleca-transactie af
  10. 04 jan Galapagos in zee met Thermo Fisher

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!